New research from Dana-Farber suggests that personalized education, coaching, and supportive resources could improve access to precision medicine by lowering the barriers to tumor genomic testing and clinical trial enrollment. more ›

A novel antibody drug-conjugate therapy has been granted accelerated approved by the FDA for the treatment of metastatic HR+, HER2- breast cancer, based on the results of a Dana-Farber study. more ›